NSi-189 foda (1270138-40-3)

NSi-189 foda (1270138-40-3) bidiyo

 

NSi-189 foda (1270138-40-3) Base Information

sunan	NSi-189 foda
CAS	1270138-40-3
tsarki	98%
Chemical name	(4-benzylpiperazin-1-yl) (2- (isopentylamino) pyridin-3-yl) methanone
nufin abu ɗaya ne	NSI-189; NSI 189; NSI189
kwayoyin Formula	C22H30N4O
kwayoyin Weight	366.4998 g / mol
InChI Key	DYTOQURYRYYNOR-UHFFFAOYSA-N
Form	m
Appearance	fari zuwa kashe-farin m foda
Rabin Rayuwa	17.4 zuwa 20.5 hours
solubility	Soluble a DMSO, ba cikin ruwa ba
Storage Yanayin	Dry, duhu kuma a 0 - 4 C don gajere (kwanaki zuwa makonni) ko -20 C na dogon lokaci (watanni zuwa shekaru).
Aikace-aikace	NSI-189 shine babban abu a cikin tsarin binciken magungunan mu na kwayar cutar neurogenic.
Takardar Gwaji	Ya Rasu

 

Haɗin tsakanin NSI 189 da MDDA

Akwai gwaji na asibiti da yawa a yanzu waɗanda suke da alama suna da alaƙa da NSI 189 da kuma lura da Rashin damuwa na rashin damuwa. Ana kuma ganin magungunan a matsayin mai bayar da magani don inganta cutar neuro-degeneration da sauran nau'ikan na fahimtar hankali. Aiki na farko na gwajin foda foda na foda na NSI 189 na MDD ya fara ne a cikin 2011

An ba da magani ga manya masu lafiya 41. Kashi na biyu na farkon farko sai a fara a shekarar 2012 inda aka yi wa membobi 24 rajista. An kammala hanyoyin farko a cikin 2014 kuma an fitar da sakamakon gwaji bisa hukuma a cikin 2015. Sakamakon gwaje-gwajen ya nuna cewa NSI 189 ta gaza cika ingancin MDD. Neuralstem ya kuma sanar a cikin 2017 cewa wani gwaji na asibiti wanda ya shafi kusan batutuwan gwajin 220 suma sun kasa cika matakan da ake buƙata don maganin MDD.

Amma akwai wasu revean wahayi da suka yi kama da masu ƙarin haske. Cikakkun labaran game da waɗannan gwaje-gwajen asibiti sun gano cewa, kodayake maganin bai kai ga matakan tasiri da ake buƙata don kula da MDD ba, marasa lafiya waɗanda suka karɓi milligram 40 a rana sun ba da rahoton ci gaba mai ƙarfi a cikin baƙin ciki.

An kuma lura cewa nauyin 40 mg nsi-189 yana da ƙarin fa'idodi na fahimi ga marasa lafiya gami da haɓaka ƙwaƙwalwa. Neuralstem ya kuma ce yana neman bin NSI 189 a matsayin magani mai yuwuwa ga sauran yanayin jijiyoyin jiki da suka hada da raunin ƙwaƙwalwar ƙwaƙwalwa, PTSD, da ƙwarewar tunani da ƙwaƙwalwar ajiya a tsufa.

 

Menene NSI 189 foda?

Labaran NSI-189 masu bita sun nuna cewa NSI-189 magani ne karkashin wani kamfani na Amurka da ake kira Neuralstem Inc. Magungunan ya kasance yana ci gaba shekaru. An fara gwajin farko ne shekaru bakwai da suka gabata. Da farko, ana ganin NSI 189 a matsayin mai ba da magani ga MD amma har yanzu gwajin asibiti bai tabbatar da wannan ba. Koyaya, akwai yuwuwar bincika NSI 189 azaman Nootropic.

Gwaje-gwaje na asibiti da aka yi akan marasa lafiya sun nuna cewa batutuwan gwaji da ke tattare da gwajin sun sami damar ba da rahoton ci gaban ƙwaƙwalwar ajiya. Ko wannan hanyar da masana'anta ke son tafiya ya kasance za'a gan ta. Amma idan kayi la'akari da koma-baya game da nazarin magungunan don MDD, bincika shi azaman magani ne mai yiwuwa don asarar ƙwaƙwalwar ajiya da sauran rashin fahimta na iya zama hanya ta gaba.

 

Yaya NSI 189 yake Aiki?

Akwai kadan bayanai game da yadda NSI-189 dopamine ke aiki. Wannan ya faru ne saboda gwaji na asibiti na miyagun ƙwayoyi sun kasance kaɗan kaɗan kuma ayyukan ba a fahimta sosai.

Koyaya, daga farkon binciken har zuwa yanzu, masana kimiyya sunyi imanin cewa NSI 189 tana aiki ta hanyar inganta neurogenesis a cikin jiki. Wannan shine aiwatar dashi ta hanyar da ake samarda sabbin jijiya da kwakwalwa. Hakanan akwai bincike wanda ke nuna cewa NSI 189 tana da babban tasiri akan hippocampus. Wannan shine yankin kwakwalwa da ke da alaƙa da tunani, ƙwaƙwalwa, da kuma ilmantarwa.

Har zuwa yanzu, wasu bincike na hakika akan mice sun nuna cewa gabatarwar NSI 189 na iya tayar da jijiyar neurogenesis a cikin hippocampus. An kuma kirkiri sakamakon iri daya a cikin binciken kwayar mutum. Amma me yasa wannan yake da mahimmanci? Idan akwai ci gaba da juyawar kwayar halitta a cikin hippocampus, yana nufin ayyukansa na hankali zai inganta sosai. Wannan shine ainihin dalilin da yasa NSI-189 yayi nazari ya nuna kyakkyawan iya gwargwadon yiwuwar Nootropic.

 

Tasirin Tasirin NSI 189

Tun da NSI 189 magani ne na gwaji, babu wani ingantacciyar hanyar tantance tasirin sa har ya zuwa yanzu. Koyaya, wasu gwaji na asibiti na iya bayar da shawarar za a iya amfani da maganin don magance maganganu da dama.
Ga sauyi mai sauƙi ga duk tasirin NSI 189:

1.Tsarin Babbar Rashin Damuwa

Kodayake gwajin da Neuralstem INC ya yi ya nuna cewa NSI 189 bai kai ga ingantattun matakan da ake buƙata don kula da MDD ba, ƙwayar ta nuna alƙawura da yawa yayin karatun. Wani bincike mai zurfi game da binciken gwajin ya nuna cewa mutanen da aka kula da su tare da miyagun ƙwayoyi yayin binciken sun ba da rahoton ci gaba mai ƙarfi a cikin baƙin ciki. Abinda ya kara ban sha'awa shine gaskiyar cewa babu wani mummunan sakamako da aka samu yayin rahoton shari'ar.

2. Inganta Inganta

Nazarin asibiti a kan NSI 189 kuma ya bayyana cewa miyagun ƙwayoyi na iya yin tasirin gaske kan haɓakar aikin fahimi. Dangane da tambayoyin kai rahoton tambayoyin da aka gudanar ga abubuwan gwajin da ke tattare da gwajin, mafi yawan mutane sun sami damar ganin ci gaba a ƙwaƙwalwar ajiya bayan shan miyagun ƙwayoyi.
Har ila yau, Neuralstem ya gano cewa mutane 220 da suka shiga cikin gwajin asibiti sun nuna ingantattun cigaba a ƙwaƙwalwar ajiya, ƙwaƙwalwar aiki, da aikin zartarwa a cikin mahalarta binciken. Wannan shine dalilin da yasa kamfanin ya bi magungunan a matsayin magani mai yuwuwar magani na rashin fahimta a nan gaba.

3. Batutuwa masu dangantaka da Ischemic Stroke

Wasu nazarin sun nuna NSI 189 na iya taimakawa wajen haɓaka ƙarancin kwakwalwa da rashin ƙarfi bayan raunin ischemic. Duk da cewa ya zuwa yanzu waɗannan karatun an yi ne akan beraye, suna alƙawarin. Bugu da ƙari, gwaje-gwajen da aka yi akan sel na mutum ya nuna cewa NSI 189 na iya juyar da mutuwar kwayar halitta wanda ta haifar da ƙarancin oxygen.

4.Cutar Al'aura

Cutar Angleman cuta ce ta ƙwaƙwalwa da za ta iya shafar tsarin juyayi. Yana iya haifar da amo, raunin ci gaban ƙasa, da ƙalubalen ilimi. Shaida daga binciken bera ya nuna cewa ana iya amfani da NSI 189 don jujjuya fahimta da raunin motsi da Angleman Syndrome ya haifar.

 

Yadda ake ɗaukar NSI 189

Ba a bayyana adadin maganin don N 189 189 ba tunda har yanzu maganin yana gwaji. Za mu iya ba ku bayani game da gudanarwa na gwaji na asibiti. Har zuwa yanzu, maganin yana shiga cikin bakin. A cikin gwaje-gwajen da aka yi a cikin shekaru bakwai da suka gabata, an gudanar da NSI XNUMX a cikin allurai daban-daban.

Groupungiyar rukuni na gwajin ya sami kashi 40 MG NSI-189 a rana ɗaya da sauran 80 MG a rana. Hakanan akwai wani rukuni wanda aka ba shi har zuwa 120 MG a rana a cikin maganin NSI-189. Maganin 40 mg yana da mafi kyawun sakamako akan abubuwan gwajin, musamman a inganta ƙwaƙwalwar ajiya. Hakanan ana sayar da NSI 189 a matsayin foda kuma ana iya haɗa shi da ruwa kafin a saka shi a ciki.

 

Hanyar Hanyar NSI 189

A lokacin gwaji na asibiti na maganin Nodi 189 curcumin, ba a ruwaito sakamako masu ƙarancin sakamako ba. NSI 189 gaba ɗaya ana ɗaukar magani mara lafiya don amfani. Koyaya, mun ga lokuta a cikin NSI 189 sakamakon Reddit sake dubawa inda masu amfani suka bayar da rahoton fuskantar fushin rashin hankali bayan amfani da miyagun ƙwayoyi. NSI 189 na iya haifar da gajiya a wasu marassa lafiya, tashin hankali, amai, matsewar jama'a, da ciwon kai. Koyaya, waɗannan tasirin sakamako zasu bambanta daga mutum zuwa wani. Hakanan suna iya aiki sosai kuma ya kamata su rabu bayan 'yan awanni. Idan sakamako masu illa sun dawwama cikin dogon lokaci, nemi shawarar likita.

 

Nasarar Binciken NSI 189

An haɓaka NSI 189 a matsayin mai yiwuwa don magance Ciwon Rashin damuwa. An yi gwajin asibiti guda biyu a cikin shekaru bakwai da suka gabata amma ba a yi nasara ba. Sakamakon gwaji daga gwaji na asibiti ya nuna cewa ƙwayar ba ta cimma tasirin da ake buƙata don kula da MDD ba. Amma akwai wasu abubuwan lura a yayin gwaji.

Na farko, NSI 189 yana da babban tasiri wajen inganta rashin jin daɗi koda kuwa bai kai matakin inganci da ake buƙata ba. Hakanan miyagun ƙwayoyi sun kuma yi alkawalin a matsayin mai yiwuwa magani ga al'amuran da suka shafi fahimi ciki har da asarar ƙwaƙwalwa Researcharin bincike don gwadawa da tabbatar da wannan tuni ya ci gaba. Nazarin kan damuwa na NSI-189 suma suna da matukar alkhairi.

 

NSI 189 Foda akan layi

Idan kana son yin amfani da fa'idodin da NSI-189 Nootropic ke bayarwa, zaka iya siyan foda akan layi. Akwai shafukan siye da yawa na NSI-189 amma ba dukansu suke ɗaukar samfuri na gaske ba. A wannan yanayin, kuna iya so ku ɗauki lokacinku. NSI-189 masu samar da foda waɗanda ke da wasu rikodin waƙa don samar da samfuran NSI 189 masu kyau ya kamata su kasance a cikin jerin ku.

Duba dubai na sauran masu amfani suma. Za su iya taimaka maka cikin sauƙi a iya sanin waɗanne samfura waɗanda za a yarda da su, kuma waɗanne za ka guji. NSI 189 anhedonia magani ne na gwaji don haka babu bayanai da yawa game da ita. Kawai ɗauki lokacinku don ƙarin koyo game da miyagun ƙwayoyi, amfaninsa, da tasirinsa kafin ku fara amfani da shi. Samu babban mai samar da foda NSI 189 foda kuma ka guji batutuwa.

 

NSi-189 (1270138-40-3) Tunani

1.  Fava M, Johe K, Ereshefsky L, Gertsik LG, Turanci BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. Tsarin 1B, bazuwar, makafi sau biyu, sarrafawar placebo, nazarin haɓaka mai yawa na NSI-189 phosphate, mahaɗin neurogenic, a cikin marasa lafiya masu baƙin ciki. Mol Psychiatry. 2016 Oct; 21 (10): 1372-80. doi: 10.1038 / mp.2015.178. PubMed PMID: 26643541; PubMed Central PMCID: PMC5030464.
2.  Fava M, Johe K, Ereshefsky L, Gertsik LG, Turanci BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. Tsarin 1B, bazuwar, makafi sau biyu, sarrafawar placebo, nazarin haɓaka mai yawa na NSI-189 phosphate, mahaɗin neurogenic, a cikin marasa lafiya masu baƙin ciki. Mol Psychiatry. 2016 Oct; 21 (10): 1483-4. doi: 10.1038 / mp.2016.140. PubMed PMID: 27528461; PubMed Central PMCID: PMC5030463